课题基金 / 基金详情

Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013

Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013
基本标题：预防临床前药理学和毒理学任务订单标题：使用人单克隆抗体 ATI-1013 进行尼古丁减少治疗
批准号：
10932479
负责人：
DAVID MCCORMICK
金额：
$65.95万
依托单位：
IIT RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
项目状态：
已结题
起止时间：
2023-09-22 至 2024-05-21
来源：
https://reporter.nih.gov/project-details/10932479
关键词：
AdoptedAmerican Association of Cancer ResearchAnimal Cancer ModelAntibodiesBindingBiological AssayBiological ProductsCCL2 geneCanis familiarisCellular AssayClinical ChemistryCommunitiesConsultationsContractorContractsDevelopmentDoseDrug KineticsEnzyme-Linked Immunosorbent AssayEuropeanEvaluationExposure toFrequenciesFundingGuidelinesHalf-LifeHematologyHumanHuman ResourcesIL17 geneIL8 geneIn VitroIncubatedInterferonsInterleukin-10Interleukin-2Interleukin-6IntravenousInvestigationLesionMalignant NeoplasmsMaximum Tolerated DoseMeasuresMedicineMethodsMissionMonoclonal AntibodiesNicotineNotificationOrganPathologyPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacologyPrincipal InvestigatorProductionProgress ReportsRattusRecommendationReportingResearchRouteSamplingSerumSlideSpecific qualifier valueTechnologyTestingTissuesToxicologyTravelbasecancer preventioncarcinogenesisclinical translationcross reactivitycytokinecytotoxicityhuman monoclonal antibodieshuman tissueimmunogenicimmunogenicityinnovationmanufacturemeetingsnonhuman primatenovelposterspre-clinicalpreventive interventionprogramsresearch and developmentsymposiumvaccinology

项目摘要

项目成果

DAVID MCCORMICK的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objectives of this Task Order are to: 1. Determine the cross-reactivity of ATI-1013 in major organs/tissues of humans, rats, dogs, and non-human primates. 2. Assess immunogenicity of ATI-1013 in a peripheral blood mononuclear cell assay. 3. Conduct a dose range finding and pharmacokinetics study in rats to determine the maximum feasible/tolerated dose of ATI-1013 and single-dose ATI-1013 pharmacokinetics at that dose. 4. Investigate the production of antidrug antibodies (ADA) to ATI-1013. 5. Disseminate research findings.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIO
  • 批准号：
    10710462
  • 项目类别：
  • 资助金额：
    $0.3万
  • 财政年份：
    2022
  • 负责人：
    DAVID MCCORMICK
  • 依托单位：
    IIT RESEARCH INSTITUTE
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
  • 批准号：
    10802090
  • 项目类别：
  • 资助金额：
    $145.68万
  • 财政年份：
    2022
  • 负责人：
    DAVID MCCORMICK
  • 依托单位：
    IIT RESEARCH INSTITUTE
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
  • 批准号：
    10605054
  • 项目类别：
  • 资助金额：
    $75.0万
  • 财政年份：
    2022
  • 负责人：
    DAVID MCCORMICK
  • 依托单位：
    IIT RESEARCH INSTITUTE
TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTIONPERIOD OF PERFORMANCE: 09/21/2020 - 03/31/2023
  • 批准号：
    10551020
  • 项目类别：
  • 资助金额：
    $15.66万
  • 财政年份：
    2020
  • 负责人：
    DAVID MCCORMICK
  • 依托单位：
    IIT RESEARCH INSTITUTE